About Altasciences
Saving You Time With Tell Us Once™
Video — A Seamless CRO Experience
At Altasciences, our integrated, full-service solutions from lead candidate selection to clinical proof of concept are all customizable to your specific needs. Watch as Ingrid Holmes, Vice President, Global Clinical Operations, discusses how we help sponsors bring better drugs to market, faster. |
Contact our experts to learn more about our integrated drug development solutions. |
Study Site Management: Eight Reasons to Choose Altasciences
An important consideration in choosing a research partner for your drug development programs is their experience and expertise in managing their study sites.
Get Up Close and Personal with Dr. Anahita Keyhani, PhD
Dr. Anahita Keyhani is Altasciences' Senior Director of Scientific Operations, Mass Spectrometry and Method Development.
Up Close and Personal with Francis Douville
Francis Douville joined the Altasciences team in 2018, as Senior Vice President, Technical Operations, for our preclinical services.
2019 Year in Review
Up Close and Personal with David Grégoire
David Grégoire joined Altasciences as Director of Quality Assurance in 2012.
Up Close and Personal with Mike Broadhurst
Mike Broadhurst joined the Altasciences’ team in 2018.
Brand Identity – Altasciences’ Evolution
Developing a brand identity that fully expresses your company’s contributions is a process that involves understanding your position in the marketplace, establishing your unique selling proposition and associated messaging, developing memorable and impactful creative elements, and finally, implementing strategies to support your brand identity.
Letter From Altasciences' CEO
February 12, 2019
Exceptional service — Lately, it has become an overused expression in our industry. About a year ago, Altasciences set out to explore what exceptional service really means to the people who matter — our clients. After extensive discussions, client surveys, and evaluations, we were pleased to confirm that our early drug development solution offering enables us to provide what our clients want. We also discovered that our brand identity did not accurately communicate our combined early stage drug development capabilities and expertise.